Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence-Reference-Cited by-同舟云学术

Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence

Published:2022-11-05 Issue:1 Volume:41 Page:35-43
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Shima Yusuke,Sato Yuki,Morimoto Takeshi,Hara Shigeo,Hirabayashi Ryosuke,Nagata Kazuma,Nakagawa Atsushi,Tachikawa Ryo,Hamakawa Hiroshi,Takahashi Yutaka,Tomii Keisuke

Funder

Kasahara Cancer

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-022-01309-4.pdf

Reference19 articles.

1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

2. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén O, Frontera L, Havel M, Steins MC, Garassino JG, Aerts M, Domine L, Paz-Ares M, Reck C, Baudelet CT, Harbison B, Lestini DR, Spigel (2015) Nivolumab versus docetaxel in Advanced squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627

3. Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M, Yokoi K (2011) Japanese Joint Committee of Lung Cancer Registration, Japanese lung cancer registry study of 11,663 surgical cases in 2004: Demographic and prognosis changes over decade. J Thorac Oncol 6:1229–1235. https://doi.org/10.1097/JTO.0b013e318219aae2

4. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) KEYNOTE-024 Investigators, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non–Small-Cell Lung Cancer, N. Engl. J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774

5. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, Van Den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA (2017) CheckMate 026 Investigators, First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer, N. Engl. J Med 376:2415–2426. https://doi.org/10.1056/NEJMoa1613493

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of immunotherapy in postoperative recurrent non-small cell lung cancer without EGFR mutations or ALK rearrangements;Journal of Thoracic Disease;2024-06